Evaluation of the effect of Acadian soil health granule (SoliGro Gr) on Growth and yield of paddy ( Oryza sativa L.)

An experiment was conducted at the Student’s Instructional Farm of Chandra Sekhar Azad University of Agriculture and Technology, Kanpur during kharif season of 2017 to find out the performance of bio-stimulant (SoliGro Gr) on growth and yield of paddy and also their suitable application. The experiment comprises of ten treatments. Laid out in Randomized Block Design with three replications. The soil of the experimental field was sandy loam in texture with PH 7.6 and EC of 0.37 mm hos m-1 at 25oC. It contained 0.4% organic carbon, 183.0 kg available N/ha, 18.0 kg available phosphorous/ha and 235 kg/ha available potassium. The recommended dose of fertilizes (NPK:120:60:60 kg/ha) were applied uniformly in each plot. The soil Health Granule was applied at final land preparation before transplanting, 25, 45 & 65 DAT in rice crop as per treatments. Result showed that the application of RDF+SoliGro @ 10 kg/ha at FLP & 25 DAT promoted significantly the growth and yield attributes of rice crop viz. plant stand count at initial stage and also at maturity as compared to control treatment, plant height at all stages were, effective tillers/hill, number of grains/panicle, effective tillers/m2, root hairs/hill, root length, root dry weight/hill at different stages were observed significantly as compared to control treatment. Application of RDF+SoliGro @ 10 kg/ha at FLP & 25 DAT recorded significantly higher Soil Microbial Population (cfu/ml) at PDA (106 & 107 dilution) and NA (108 & 109 dilution), respectively compared to control treatment. Application of RDF+SoliGro @ 10 kg/ha at FLP & 25 DAT also recorded significantly maximum grain yield (53.46 q/ha) and harvest index (37.30%) compared to all rest treatment. The net income was increased in application of RDF with two times used SoliGro Gr @ 10 kg/ha at final land preparation and 25 days after transplanting of rice by a margin of 64.32%, 28.04%, 4.59%, 30.19%, 37.84%, 16.42%, 23.86%, 7.26% and 10.27% in respect of net return over remaining treatments, respectively.